CRISPR-Cas9 for Corneal Diseases

Professor Tara C. Moore of Ulster University discusses recent advancements of CRISPR-Cas9 for the treatment of corneal diseases. The bacterial-derived enzyme can effectively repair or knockout a target stretch of DNA without reproduction for each new target, making it simpler and more cost effective than previous gene editing methods. CRISPR-Cas9 shows great promise for the treatment of dominant negative genetic disorders such as corneal dystrophies due to the cornea’s size, accessibility and limbal location.